Optimization of Epigenetic Modifier Drug Combination for Synergistic Effect against Glioblastoma Multiform Cancer Cell Lines

References

• Reifenberger G, Wirsching H-G, Knobbe-Thomsen CB, Weller M. Advances in the molecular genetics of gliomas—implications for classification and therapy. Nat Rev Clin Oncol. 2017;14(7):434–452. doi:10.1038/nrclinonc.2016.204.
   PubMed Web of Science ®Google Scholar
• Rajesh Y, Pal I, Banik P, Chakraborty S, Borkar SA, Dey G, et al. Insights into molecular therapy of glioma: current challenges and next generation blueprint. Acta Pharmacol Sin. 2017;38(5):1–23.
   PubMed Web of Science ®Google Scholar
• Zhang Q-M, Shen N, Xie S, Bi S-Q, Luo B, Lin Y-D, et al. MAGED4 expression in glioma and upregulation in glioma cell lines with 5-aza-2'-deoxycytidine treatment. Asian Pac J Cancer Prev. 2014;15(8):3495–3501. doi:10.7314/apjcp.2014.15.8.3495.
   PubMedGoogle Scholar
• Rasime K. Epigenetics of glioblastoma multiforme. J Clin Res Bioethics. 2015;6(3):1–6.
   Google Scholar
• Holland EC. Glioblastoma multiforme: the terminator. Proc Natl Acad Sci USA. 2000;97(12):6242–6244. doi:10.1073/pnas.97.12.6242.
   PubMed Web of Science ®Google Scholar
• Juo YY, Gong XJ, Mishra A, Cui X, Baylin SB, Azad NS, Ahuja N. Epigenetic therapy for solid tumors: from bench science to clinical trials. Epigenomics. 2015;7(2):215–235. doi:10.2217/epi.14.73.
   PubMed Web of Science ®Google Scholar
• Altucci L, Minucci S. Epigenetic therapies in haematological malignancies: searching for true targets. Eur J Cancer. 2009;45(7):1137–1145. doi:10.1016/j.ejca.2009.03.001.
   PubMed Web of Science ®Google Scholar
• Altucci L, Rots MG. Epigenetic drugs: from chemistry via biology to medicine and back. Clin Epigenetics. 2016;8(1):56. doi:10.1186/s13148-016-0222-5.
   PubMedGoogle Scholar
• Mummaneni P, Shord SS. Epigenetics and oncology. Pharmacotherapy. 2014;34(5):495–505. doi:10.1002/phar.1408.
   PubMed Web of Science ®Google Scholar
• Lehár J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol. 2009;27(7):659–666. doi:10.1038/nbt.1549.
   PubMed Web of Science ®Google Scholar
• Weiss A, Berndsen RH, Ding X, Ho C-M, Dyson PJ, van den Bergh H, et al. A streamlined search technology for identification of synergistic drug combinations. Sci Rep. 2015;5(1):14508–14519. doi:10.1038/srep14508.
   PubMedGoogle Scholar
• Gomes T, Barradas C, Dias T, Verdial J, Morais JS, Ramalhosa E, et al. Optimization of mead production using response surface methodology. Food Chem Toxicol. 2013;59:680–686. doi:10.1016/j.fct.2013.06.034.
   PubMed Web of Science ®Google Scholar
• Bezerra MA, Santelli RE, Oliveira EP, Villar LS, Escaleira LA. Response surface methodology (RSM) as a tool for optimization in analytical chemistry. Talanta. 2008;76(5):965–977. doi:10.1016/j.talanta.2008.05.019.
   PubMed Web of Science ®Google Scholar
• Boubakri A, Hafiane A, Bouguecha ST. Application of response surface methodology for modeling and optimization of membrane distillation desalination process. J Ind Eng Chem. 2014;20(5):3163–3169. doi:10.1016/j.jiec.2013.11.060.
   Web of Science ®Google Scholar
• Nasrollahi P, Khajeh K, Akbari N. Optimizing of the formation of active BMW-amylase after in vitro refolding. Protein Expr Purif. 2012;85(1):18–24. doi:10.1016/j.pep.2012.06.013.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.21254.
   PubMed Web of Science ®Google Scholar
• Ahuja N, Sharma AR, Baylin SB. Epigenetic therapeutics: a new weapon in the war against cancer. Annu Rev Med. 2016;67(1):73–89. doi:10.1146/annurev-med-111314-035900.
   PubMedGoogle Scholar
• Benedetti R, Conte M, Iside C, Altucci L. Epigenetic-based therapy: from single-to multi-target approaches. Int J Biochem Cell Biol. 2015;69:121–131. doi:10.1016/j.biocel.2015.10.016.
   PubMed Web of Science ®Google Scholar
• Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife. 2013;2:e00747. doi:10.7554/eLife.00747.
   PubMed Web of Science ®Google Scholar
• Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol. 2003;21(12):2299–2304. doi:10.1200/JCO.2003.08.045.
   PubMed Web of Science ®Google Scholar
• Devita VT, Young RC, Canellos GP. Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer. 1975;35(1):98–110. doi:10.1002/1097-0142(197501)35:1<98::AID-CNCR2820350115>3.0.CO;2-B.
   PubMed Web of Science ®Google Scholar
• Miceli M, Bontempo P, Nebbioso A, Altucci L. Natural compounds in epigenetics: a current view. Food Chem Toxicol. 2014;73:71–83. doi:10.1016/j.fct.2014.08.005.
   PubMed Web of Science ®Google Scholar
• Ornstein MC, Mukherjee S, Sekeres MA. More is better: Combination therapies for myelodysplastic syndromes. Best Prac Res Clin Haematol. 2014;28(1):1–10.
   PubMed Web of Science ®Google Scholar
• Oblad R, Doughty H, Lawson J, Christensen M, Kenealey J. Application of mixture design response surface methodology for combination chemotherapy in PC-3 human prostate cancer cells. Mol Pharmacol. 2018;94(2):907–916. doi:10.1124/mol.117.111450.
   PubMed Web of Science ®Google Scholar
• Borodovsky A, Salmasi V, Turcan S, Fabius AWM, Baia GS, Eberhart CG, et al. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget. 2013;4(10):1737–1747. doi:10.18632/oncotarget.1408.
   PubMed Web of Science ®Google Scholar
• Chen M-Y, Liao WS-L, Lu Z, Bornmann WG, Hennessey V, Washington MN, et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer. 2011;117(19):4424–4438. doi:10.1002/cncr.26073.
   PubMed Web of Science ®Google Scholar
• Susanto JM, Colvin EK, Pinese M, Chang DK, Pajic M, Mawson A, et al. The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2'deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo. Int J Oncol. 2015;46(5):2223–2230. doi:10.3892/ijo.2015.2894.
   PubMed Web of Science ®Google Scholar
• Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21(1):103–107. doi:10.1038/5047.
   PubMed Web of Science ®Google Scholar
• Lemaire M, Momparler LF, Bernstein ML, Marquez VE, Momparler RL. Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia. Anticancer Drugs. 2005;16(3):301–308. doi:10.1097/00001813-200503000-00009.
   PubMed Web of Science ®Google Scholar
• Stephan L, Momparler RL. Combination chemotherapy of cancer using the inhibitor of DNA methylation 5-aza-2′-deoxycytidine (decitabine). J Cancer Res Ther. 2015;3(6):56–65. doi:10.14312/2052-4994.2015-8.
   Google Scholar
• Ott HM, Graves AP, Pappalardi MB, Huddleston M, Halsey WS, Hughes AM, et al. A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation. Mol Cancer Ther. 2014;13(12):3062–3073. doi:10.1158/1535-7163.MCT-13-0876.
   PubMed Web of Science ®Google Scholar
• Tiffen JC, Gunatilake D, Gallagher SJ, Gowrishankar K, Heinemann A, Cullinane C, et al. Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. Oncotarget. 2015;6(29):27023–27036. doi:10.18632/oncotarget.4809.
   PubMedGoogle Scholar
• Van Aller GS, Pappalardi MB, Ott HM, Diaz E, Brandt M, Schwartz BJ, et al. Long residence time inhibition of EZH2 in activated polycomb repressive complex 2. ACS Chem Biol. 2013;9(3):622–629. doi:10.1021/cb4008748.
   PubMed Web of Science ®Google Scholar
• Momparler RL, Côté S, Momparler LF, Idaghdour Y. Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation. Clin Epigenet. 2014;6(1):19. doi:10.1186/1868-7083-6-19.
   PubMedGoogle Scholar
• Momparler RL, Idaghdour Y, Marquez VE, Momparler LF. Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation. Leuk Res. 2012;36(8):1049–1054. doi:10.1016/j.leukres.2012.03.001.
   PubMed Web of Science ®Google Scholar
• Mayr C, Wagner A, Loeffelberger M, Bruckner D, Jakab M, Berr F, et al. The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Oncotarget. 2016;7(1):745–758. doi:10.18632/oncotarget.6378.
   PubMedGoogle Scholar
• Alzrigat M, Párraga AA, Majumder MM, Ma A, Jin J, Österborg A, et al. The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains. Oncotarget. 2017;8(61):103731–103743. doi:10.18632/oncotarget.21909.
   PubMedGoogle Scholar
• Cheng Y, He C, Wang M, Xuelei M, Mo F, Yang S, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4(62):1–39.
   PubMedGoogle Scholar
• Vijayaraghavalu S, Dermawan JK, Cheriyath V, Labhasetwar V. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. Mol Pharm. 2013;10(1):337–352. doi:10.1021/mp3004622.
   PubMed Web of Science ®Google Scholar